Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a pilot, open-label, phase II study. The main objective of the study is to
demonstrate that Cannabidiol (CBD), used in addition to current anti-seizure medications
(ASMs) reduces the number and/or severity of motor (generalized, focal, or both) seizures in
children and young adults with rare disease-associated severe epilepsy.
Secondary objectives include assessment of safety and tolerability, changes in behaviour,
cognition and sleep, pharmacokinetic interaction with concurrent ASMs.